Treatment and Prevention of Migraine
Migraine exerts a significant impact on quality of life. Several drugs are available for acute therapy of migraine attacks, namely, specific such as triptans or generic such as analgesics/anti-inflammatory. In some cases, prophylaxis therapy is taken into account according to both attack frequency and severity. In the past, the most common criterion applied for prophylaxis therapy was represented by the number of attacks per month. Considering such a pattern essential, the suggested number of attacks per month was of five or more episodes. At a later date, demand for prophylaxis also considered consumption of symptomatic drugs as well as increase of migraine frequency in a short period of time. Today, prophylaxis therapy is evaluated according to its impact on patients. Therefore, a general evaluation of the patient in terms of functional disability and quality of life is required to assess the appropriateness of prophylaxis therapy, as well as evaluating the risk of medication overuse or the presence of concomitant pathologies (e.g., hypertension, depression, epilepsy). Furthermore, in cases where the condition reaches a level of chronicity (chronic migraine), new options are available today in prophylaxis therapy.
KeywordsMigraine Attack Chronic Migraine Naproxen Sodium Preventive Therapy Sodium Valproate
- Diener HC, Tfelt-Hansen P, Dahlöf C et al (2004) Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 25:943–950Google Scholar
- Linde E, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:D003225Google Scholar
- Sandrini G, Cerbo R, Del Bene E et al (2007) Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract 61:1256–1269PubMedCrossRefGoogle Scholar
- Steiner TJ, Paemeleire K, Jensen R (2007) European principles of management of common headache disorders in primary care. J Headache Pain 8:S1–S47Google Scholar
- The Diclofenac-K/Sumatriptan Migraine Study Group, Bussone G, Grazzi L, D'Amico D (1999) Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 19:232–240CrossRefGoogle Scholar